Canadian researchers found that prostate cancer patients who carry BRCA1 and BRCA2 -- defective genes that are associated with ovarian cancer and an increased breast cancer risk among women -- had post-diagnosis survival times that fell short of the 12-year average for men. Patients with the BRCA1 gene lived on average for eight years while those with the BRCA2 survived on average for four years after diagnosis, according to the study.

Full Story:

Related Summaries